{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.82","upperLimit":"16.69","value":"9.95"},{"groupId":"OG001","lowerLimit":"4.50","upperLimit":"9.03","value":"6.37"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"title":"PD-L1 expression >= 5%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.49","upperLimit":"12.62","value":"8.54"},{"groupId":"OG001","lowerLimit":"5.13","upperLimit":"8.28","value":"6.14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"69"}],"units":"Participants"}],"title":"PD-L1 expression < 5%"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.10","upperLimit":"25.20","value":"9.41"},{"groupId":"OG001","lowerLimit":"3.02","upperLimit":"6.11","value":"5.06"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"29"}],"units":"Participants"}],"title":"PD-L1 not quantifiable at baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"137"}],"units":"Participants"}],"description":"OS was measured in months for all randomized participants grouped by their baseline PD-L1 expression level. PD-L1 expression was defined as the percent of disease tumor cells demonstrating plasma membrane PD-L1 staining of any intensity using an immunohistochemistry (IHC) assay. OS was defined as the time between the date of randomization and the date of death from any cause. Participants were censored at the date they were last known to be alive. Median OS time was calculated using Kaplan-Meier (KM) method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.","id":"OG000","title":"Nivolumab"},{"description":"Docetaxel 75mg/m\\^2 solution intravenously every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or study ends.","id":"OG001","title":"Docetaxel"}],"paramType":"MEDIAN","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From the date of randomization to the date of death from any cause, up to approximately 103 months","title":"Overall Survival (OS) Time in Months by Baseline PD-L1 Expression for All Randomized Participants","type":"SECONDARY","unitOfMeasure":"Months"}